Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland - Full Text View

Purpose

Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.

Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.

Condition

Hepatitis C, Chronic
Substance Abuse Treatment Centers
Opioid-Related Disorders

MedlinePlus related topics:

Hepatitis Hepatitis C

ChemIDplus related topics:

Methadone Methadone hydrochloride Interferon alfa-2b Interferons Buprenorphine Buprenorphine hydrochloride Diacetylmorphine Diacetylmorphine hydrochloride

U.S. FDA Resources

Study Type:	Observational
Study Design:	Retrospective

Official Title:	Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung

Further study details as provided by Seidenberg, Arztpraxis A., M.D.:

Study Start Date:	July 2007
Study Completion Date:	December 2007

Detailed Description:

www.seidenberg.ch/hepcop.pdf

Eligibility

Genders Eligible for Study:

Both

Study Population

Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland

Criteria

Inclusion Criteria:

Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00473993

Sponsors and Collaborators

Seidenberg, Arztpraxis A., M.D.

University of Zurich

Investigators


Study Director:	André Seidenberg, Dr.med.	research fellow EHAM, University of Zurich

More Information

download of the protocol of the HepCOP-study This link exits the ClinicalTrials.gov site

Study ID Numbers:	HepCOP Zurich
First Received:	May 15, 2007
Last Updated:	April 25, 2008
ClinicalTrials.gov Identifier:	NCT00473993
Health Authority:	Switzerland: Ethikkommision

Keywords provided by Seidenberg, Arztpraxis A., M.D.:

Hepatitis C

Opioid Maintenance Treatment

Methadone

Buprenorphine

Heroin

Interferon, pegylated

Study placed in the following topic categories:

Liver Diseases

Hepatitis, Chronic

Heroin

Interferons

Hepatitis, Viral, Human

Disorders of Environmental Origin

Opioid-Related Disorders

Hepatitis

Virus Diseases

Methadone

Buprenorphine

Digestive System Diseases

Mental Disorders

Substance-Related Disorders

Hepatitis C

Hepatitis C, Chronic

Interferon Alfa-2b

Additional relevant MeSH terms:

RNA Virus Infections

Flaviviridae Infections

ClinicalTrials.gov processed this record on September 05, 2008

Sponsors and Collaborators:	Seidenberg, Arztpraxis A., M.D. University of Zurich
Information provided by:	Seidenberg, Arztpraxis A., M.D.
ClinicalTrials.gov Identifier:	NCT00473993